Fulgent Genetics, Inc. NASDAQ:FLGT

Fulgent Genetics stock price today

$21.57
+3.19
+17.42%
Financial Health
0
1
2
3
4
5
6
7
8
9

Fulgent Genetics stock price monthly change

-12.31%
month

Fulgent Genetics stock price quarterly change

-12.31%
quarter

Fulgent Genetics stock price yearly change

-39.07%
year

Fulgent Genetics key metrics

Market Cap
555.76M
Enterprise value
870.71M
P/E
6.83
EV/Sales
1.40
EV/EBITDA
3.89
Price/Sales
1.50
Price/Book
0.73
PEG ratio
-0.09
EPS
-5.57
Revenue
287.53M
EBITDA
-46.34M
Income
-165.94M
Revenue Q/Q
-2.54%
Revenue Y/Y
-21.19%
Profit margin
23.17%
Oper. margin
29.32%
Gross margin
59.28%
EBIT margin
29.32%
EBITDA margin
-16.12%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Fulgent Genetics stock price history

Fulgent Genetics stock forecast

Fulgent Genetics financial statements

Fulgent Genetics, Inc. (NASDAQ:FLGT): Profit margin
Jun 2023 67.85M -11.22M -16.55%
Sep 2023 84.68M -13.10M -15.48%
Dec 2023 70.50M -128.14M -181.76%
Mar 2024 64.48M -13.46M -20.88%
Fulgent Genetics, Inc. (NASDAQ:FLGT): Analyst Estimates
Sep 2025 81.83M -4.00M -4.89%
Oct 2025 82.85M -4.82M -5.82%
Dec 2025 85.48M -8.53M -9.99%
Mar 2026 83.11M -8.20M -9.88%
  • Analysts Price target

  • Financials & Ratios estimates

Fulgent Genetics, Inc. (NASDAQ:FLGT): Debt to assets
Jun 2023 1354577000 91.25M 6.74%
Sep 2023 1358398000 96.56M 7.11%
Dec 2023 1273109000 139.82M 10.98%
Mar 2024 1229885000 103.23M 8.39%
Fulgent Genetics, Inc. (NASDAQ:FLGT): Cash Flow
Jun 2023 9.73M -1.09M -16.25M
Sep 2023 10.24M 20.07M -4.47M
Dec 2023 14.93M 24.27M -25.95M
Mar 2024 7.26M -47.18M -2.80M

Fulgent Genetics alternative data

Fulgent Genetics Social Media Accounts

What are followers?
Fulgent Genetics, Inc. (NASDAQ:FLGT): Followers count
May 2025 1137
Jul 2025 1147
Aug 2025 1171

Next Generation Sequencing

Fulgent Genetics, Inc. (NASDAQ:FLGT): Google Trends - Next Generation Sequencing
12 Feb 2023 60
19 Feb 2023 51
26 Feb 2023 55
5 Mar 2023 49
12 Mar 2023 71
19 Mar 2023 43
26 Mar 2023 71
2 Apr 2023 56
9 Apr 2023 69
16 Apr 2023 45
23 Apr 2023 70
30 Apr 2023 66
7 May 2023 45
14 May 2023 63
21 May 2023 54
28 May 2023 60
4 Jun 2023 51
11 Jun 2023 57
18 Jun 2023 60
25 Jun 2023 64

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Fulgent Genetics, Inc. (NASDAQ:FLGT): Job openings
Aug 2023 4
Sep 2023 2
Oct 2023 3
Nov 2023 1
Dec 2023 3
Jan 2024 6
Feb 2024 5
Apr 2024 2
May 2024 67
Jun 2024 66
Jul 2024 70
Fulgent Genetics, Inc. (NASDAQ:FLGT): Employee count
Aug 2023 1,012
Sep 2023 1,012
Oct 2023 1,012
Nov 2023 1,012
Dec 2023 1,012
Jan 2024 1,012
Feb 2024 1,012
Mar 2024 1,184
Apr 2024 1,184
May 2024 1,184
Jun 2024 1,184
Jul 2024 1,184

Fulgent Genetics other data

39.36% +3.36%
of FLGT is owned by hedge funds
12.19M +970.31K
shares is hold by hedge funds

Fulgent Genetics, Inc. (NASDAQ:FLGT): Insider trades (number of shares)
Period Buy Sel
Aug 2024 0 4324
Sep 2024 0 4771
Nov 2024 0 3413
Dec 2024 0 2828
Transaction Date Insider Security Shares Price per share Total value Source
Sale
XIE JIAN officer: Presiden.. Common Stock 1,455 $19.5 $28,373
Sale
GAO HANLIN officer: Chief Scientific Officer
Common Stock 1,373 $19.5 $26,774
Sale
HSIEH MING director, 10 perc.. Common Stock 2,227 $18.26 $40,663
Sale
GAO HANLIN officer: Chief Scientific Officer
Common Stock 497 $18.26 $9,075
Sale
XIE JIAN officer: Presiden.. Common Stock 689 $18.26 $12,580
Sale
KIM PAUL officer: CFO and .. Common Stock 1,674 $21.96 $36,763
Sale
XIE JIAN officer: Presiden.. Common Stock 1,594 $21.96 $35,006
Sale
GAO HANLIN officer: Chief Scientific Officer
Common Stock 1,503 $21.96 $33,007
Sale
GAO HANLIN officer: Chief Scientific Officer
Common Stock 563 $22.83 $12,855
Sale
XIE JIAN officer: Presiden.. Common Stock 715 $22.83 $16,326
Insider Compensation
Mr. Paul Kim (1967) Chief Financial Officer $253,660
Mr. Ming Hsieh (1956) Chairman, Chief Executive Officer & Pres $248,000
Mr. Jian Xie (1966) Chief Operating Officer $224,540
Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. (1967) Chief Scientific Officer & Laboratory Director
$223,510
Tuesday, 24 December 2024
seekingalpha.com
Monday, 9 December 2024
zacks.com
Friday, 22 November 2024
zacks.com
zacks.com
Monday, 11 November 2024
seekingalpha.com
Friday, 8 November 2024
zacks.com
businesswire.com
Tuesday, 5 November 2024
businesswire.com
Friday, 1 November 2024
zacks.com
Thursday, 31 October 2024
businesswire.com
Thursday, 17 October 2024
businesswire.com
Wednesday, 25 September 2024
seekingalpha.com
Monday, 9 September 2024
seekingalpha.com
Tuesday, 13 August 2024
zacks.com
zacks.com
Friday, 2 August 2024
zacks.com
businesswire.com
Thursday, 18 July 2024
zacks.com
Monday, 10 June 2024
globenewswire.com
Monday, 3 June 2024
businesswire.com
Friday, 24 May 2024
businesswire.com
Tuesday, 14 May 2024
businesswire.com
Friday, 3 May 2024
Zacks Investment Research
Thursday, 11 April 2024
Business Wire
Saturday, 25 November 2023
InvestorPlace
Friday, 3 November 2023
Seeking Alpha
Friday, 4 August 2023
Zacks Investment Research
Saturday, 29 July 2023
Seeking Alpha
Tuesday, 6 June 2023
The Motley Fool
Tuesday, 23 May 2023
The Motley Fool
  • What's the price of Fulgent Genetics stock today?

    One share of Fulgent Genetics stock can currently be purchased for approximately $21.57.

  • When is Fulgent Genetics's next earnings date?

    Unfortunately, Fulgent Genetics's (FLGT) next earnings date is currently unknown.

  • Does Fulgent Genetics pay dividends?

    No, Fulgent Genetics does not pay dividends.

  • How much money does Fulgent Genetics make?

    Fulgent Genetics has a market capitalization of 555.76M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 53.27% to 289.21M US dollars.

  • What is Fulgent Genetics's stock symbol?

    Fulgent Genetics, Inc. is traded on the NASDAQ under the ticker symbol "FLGT".

  • What is Fulgent Genetics's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of Fulgent Genetics?

    Shares of Fulgent Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Fulgent Genetics's key executives?

    Fulgent Genetics's management team includes the following people:

    • Mr. Paul Kim Chief Financial Officer(age: 58, pay: $253,660)
    • Mr. Ming Hsieh Chairman, Chief Executive Officer & Pres(age: 69, pay: $248,000)
    • Mr. Jian Xie Chief Operating Officer(age: 59, pay: $224,540)
    • Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. Chief Scientific Officer & Laboratory Director(age: 58, pay: $223,510)
  • How many employees does Fulgent Genetics have?

    As Jul 2024, Fulgent Genetics employs 1,184 workers.

  • When Fulgent Genetics went public?

    Fulgent Genetics, Inc. is publicly traded company for more then 8 years since IPO on 29 Sep 2016.

  • What is Fulgent Genetics's official website?

    The official website for Fulgent Genetics is fulgentgenetics.com.

  • Where are Fulgent Genetics's headquarters?

    Fulgent Genetics is headquartered at 4978 Santa Anita Avenue, Temple City, CA.

  • How can i contact Fulgent Genetics?

    Fulgent Genetics's mailing address is 4978 Santa Anita Avenue, Temple City, CA and company can be reached via phone at +62 635 00537.

Fulgent Genetics company profile:

Fulgent Genetics, Inc.

fulgentgenetics.com
Exchange:

NASDAQ

Full time employees:

1,184

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

4978 Santa Anita Avenue
Temple City, CA 91780

CIK: 0001674930
ISIN: US3596641098
CUSIP: 359664109